Development Funding. (a) ViewRay will pay 3D Line the then U.S. Dollar equivalent of €[***] within three (3) days of the Effective Date for the engineering services required to develop/ deliver the Deliverable described in Section 2.1(a)(1).
(b) ViewRay will pay 3D Line the then U.S. Dollar equivalent of €[***] within fifteen (15) days of the Amendment Date. This €[***] payment shall be credited against the payment due 3D Line under Section 2.2(c) for the 60-Leaf MLCs to be supplied to ViewRay pursuant to Section 2.1(a)(iv).
(c) The price for the 60-Leaf MLCs to be supplied to ViewRay pursuant to Section 2.1(a)(iv) shall be [***]; the price for the 60-Leaf MLCs to be supplied to ViewRay pursuant to Section 2.5, shall provide that the cost of the Section 2.1(a)(iv) Deliverables will be adjusted accordingly if the [***]. If the parties are unable to agree upon such pricing then they shall fix such pricing at 3D Line’s Cost of Goods Sold [***]. “3D Line’s Cost of Goods Sold” shall mean the [***] (it being understood that the [***]), [***] (including [***] 60-Leaf MLCs) plus [***] allocated to the 60-Leaf MLCs in accordance with [***]. The fully-allocated cost of manufacturing shall not include [***] (that 3D Line or any third party may have) or [***] including, by way of example only, [***]. It is understood and agreed that in the event and to the extent that the Supply Agreement the parties enter into pursuant to Section 2.5 is structured so that 3D Line does not manufacture the leaves that are used in the MLCs or does not manufacture other subassemblies for such 60-Leaf MLCs that are within the scope of 3D Line’s responsibilities during the Program, then the pricing under Section 2.5 and the Supply Agreement shall be adjusted so that the costs of leaves or other subassemblies manufactured or supplied by any third party if paid by ViewRay shall be deducted from the price paid 3D Line for such MLCs; the intention of the parties being that 3D Line shall be compensated for the work it actually performs with respect to the manufacture and supply of the 60-Leaf MLCs and shall not be compensated at any “xxxx-up” for work performed by third parties with respect to such 60-Leaf MLCs, such third party work (if not paid to such third party by ViewRay) being priced at the direct cost to 3D Line for such leaves or other subassemblies.”
Development Funding. 41 4.7 Development in the ROW ................................................... 43 4.8
Development Funding. (a) Viewray will pay 3D Line the then U.S. Dollar equivalent of €[***] within three (3) days of the Effective Date for the engineering services required to develop/ deliver the Deliverable described in Section 2.1(a)(i).
Development Funding. The Union shall, through its national benefits staff, arrange for research and staff support to the parties to support the joint effort of the parties to develop this new model of retirement benefits.
Development Funding. 1. New Product Programs that are approved by the Advisory Board shall be funded as follows:
(a) [*] for New Product Programs that are * Confidential treatment has been requested for marked portion intended to develop Products that shall be marketed and sold in the Territory and NAFTA, or
(b) [*] for New Product Programs that are intended to develop Products that shall be marketed and sold only in the Territory.
2. For development work conducted by Focal and funded by Ethicon, Ethicon shall pay to Focal an amount to be agreed upon by the parties, intended to cover the direct and indirect expenses incurred by Focal in the conduct of a New Product Program.
Development Funding. According to Section 4, Amylin will pay to ACTII the FTE Hourly Rate for all work performed by ACTII under the Product Development Plan.
Development Funding. Consideration received from a Sublicensee of AgeX that is explicitly designated in the sublicense agreement to cover Development Costs will not be considered Sublicensing Considering subject to Section 2.2(d) (iii). Any Sublicensing Considering actually received by AgeX that was designated as Development Costs that were not actually incurred by AgeX as Development Costs in respect to Development of a Licensed Product, Licensed Service or Licensed Process, will become Sublicensing Consideration if not returned upon completion or termination of the project for which the consideration was so designated.
Development Funding. GSK shall, subject to the remainder of this Section 4.5, compensate CureVac for the Development Costs CureVac incurs performing the Development activities set forth in each R&D Plan (with FTE calculated at the FTE Rate) in accordance with the budget and assumptions as agreed under that R&D Plan. The Parties shall in good faith consider means of gaining efficiencies in the performance of the R&D Plans that have a positive impact on the associated budget, such as outsourcing of certain research activities to a subcontractor. The compensation is to be paid by GSK to CureVac on a Calendar Quarterly basis. GSK shall make payments to CureVac within [*****] after receipt of an invoice from CureVac, which CureVac shall provide on a Calendar Quarterly basis, with supportive documentation reasonably detailing the composition of the agreed budgeted cost (with FTE calculated at the FTE Rate) for the applicable Calendar Quarter period. CureVac shall notify GSK as soon as reasonably practicable in the event that it becomes aware that Development Costs are expected to deviate from the amounts approved in the Development budget, as a result of a change to the assumptions under the R&D Plan, whereupon the Parties shall discuss the causes of such deviation and evaluate potential mitigation measures relating thereto, and an appropriate adjustment (if any) to the Development budget. The Parties shall refer any Development budget increase amounting to greater than [*****] of the previously approved amount to the JSC for prior approval. Unless such budget increase is approved by the JSC, GSK shall not be liable to compensate any amounts to CureVac in excess of [*****] of the amount set out in the agreed Development budget from time to time. GSK shall not unreasonably withhold its approval to any budget increase which is reasonably required as a result of the change to a budgeting assumption set out in a R&D Plan.
Development Funding. Provided that this Agreement does not terminate on or before January 31, 1994, as provided in Section 4.2, during the twenty- four (24) month period after the Effective Date, NCL shall pay (or at NCL's election, it shall direct NOA to pay) to SGI the development funding agreed upon pursuant to Section 4.2, which shall consist of development fees and prepaid royalties, in the proportions provided in Attachment C. Company shall make the initial payment specified in Attachment C within five (5) days of the Effective Date as the initial nonrefundable installment of such development fees. The balance shall be paid in six (6) equal, non-refundable quarterly installments beginning on February 1, 1994, and every three (3) months thereafter.
Development Funding. The Employer shall make a grant of seventy-five thousand dollars ($75,000) to fund the infrastructure of the Trust on July 1, 2017.
